Sanofi to Acquire Blueprint Medicines for $9.5 Billion, Expanding Rare Disease Portfolio

An announcement from Sanofi ( (SNY) ) is now available.

On June 2, 2025, Sanofi announced its acquisition of Blueprint Medicines Corporation, a biopharmaceutical company known for its work in systemic mastocytosis and other KIT-driven diseases. This strategic acquisition, valued at approximately $9.5 billion, includes the addition of Ayvakit/Ayvakyt, the only approved medicine for systemic mastocytosis, to Sanofi’s portfolio. The move is expected to enhance Sanofi’s immunology pipeline and strengthen its market position in rare diseases. The acquisition is projected to be completed in the third quarter of 2025 and is anticipated to be accretive to Sanofi’s business operating income and EPS after 2026.

The most recent analyst rating on (SNY) stock is a Hold with a $67.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.

Spark’s Take on SNY Stock

According to Spark, TipRanks’ AI Analyst, SNY is a Neutral.

Sanofi’s overall stock score reflects strong earnings performance and a stable financial foundation, despite technical challenges and valuation concerns. The earnings call was particularly impactful, highlighting strategic growth areas and effective management. Technical indicators suggest a cautious approach, while the valuation is slightly stretched.

To see Spark’s full report on SNY stock, click here.

More about Sanofi

Sanofi is a global biopharmaceutical company headquartered in Paris, France, specializing in the development and commercialization of therapeutic solutions across various medical fields. The company focuses on rare diseases, immunology, oncology, and vaccines, aiming to bring innovative medicines to patients worldwide.

Average Trading Volume: 2,945,708

Technical Sentiment Signal: Hold

Current Market Cap: $121.4B

Learn more about SNY stock on TipRanks’ Stock Analysis page.